Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse MKT  >  IGI LABORIGI       

Financials ($)
Sales 2016 67,8 M
EBIT 2016 4,96 M
Net income 2016 -9,57 M
Debt 2016 49,8 M
Yield 2016 -
Sales 2017 94,7 M
EBIT 2017 13,3 M
Net income 2017 -0,31 M
Debt 2017 60,2 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 6,30x
EV / Sales2017 4,62x
Capitalization 378 M
More Financials
Teligent, Inc. develops, manufactures and markets topical formulations.The company sells generic topical pharmaceutical products under IGI label.It also provides development, formulation, and manufacturing services to the pharmaceutical, over-the-counter and cosmetic markets.The company's products... 
10/27Earnings Release
More about the company
Surperformance© ratings of IGI LABORIGI
Trading Rating : Investor Rating :
More Ratings
Latest news on IGI LABORIGI
10/14 TELIGENT, INC. : To Hold Conference Call For 3rd Quarter 2016 Results
10/11 TELIGENT : Announces The Opening Of A Product Development Laboratory In Estonia
10/05 TELIGENT : Second Teligent Topical Product Approved by Health Canada
09/30 TELIGENT : Health Canada Approves First Teligent Topical Product
09/13 TELIGENT, INC. : To Present At Morgan Stanley Global Healthcare Conference On Se..
09/01 TELIGENT : Announces Health Canada Approval Of Gentamicin Injection USP
08/25 TELIGENT, INC. : Announces Health Canada Approval Of Three Baclofen Injection Pr..
08/23 TELIGENT, INC. : Announces Health Canada Approval Of Gentamicin Injection USP
08/08 TELIGENT : Management's Discussion and Analysis of Financial Condition and Resul..
08/02 TELIGENT : Sanders Morris Harris buys $15,297,383 stake in Teligent Inc
More news
Sector news : Pharmaceuticals - NEC
04:13p GLAXOSMITHKLINE : British imports of cheap medicines dry up as pound falls
04:05pDJGlaxo Profit Jumps on Weaker Pound
09:08a Bayer third-quarter profit beats forecasts on pharma, pesticides
10/25DJMERCK : Profit Rises on Cancer Drugs, Vaccines
10/25DJMERCK : Revenue and Profit Rise on Cancer Drugs, Vaccines -- Update
More sector news : Pharmaceuticals - NEC
Duration : Period :
IGI LABORIGI Technical Analysis Chart | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 9,75 $
Spread / Average Target 37%
Consensus details
EPS Revisions
More Estimates Revisions
Jason Grenfell-Gardner President, Chief Executive Officer & Director
James Charles Gale Chairman
Sanjay Samudre Operations Director
Jenniffer L. Collins CFO, Secretary & Head-Investor Relations
Stephen Richardson Chief Scientific Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON10.94%311 781
ROCHE HOLDING LTD.-16.53%198 222
PFIZER INC.0.00%195 799
NOVARTIS AG-14.06%191 921
MERCK & CO., INC.17.29%171 305
More Results